Literature DB >> 27227483

Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.

A N Hasan1,2, A Selvakumar2, E Shabrova1, X-R Liu2, F Afridi1, G Heller3, I Riviere4, M Sadelain4, B Dupont2,5, R J O'Reilly6,7,8.   

Abstract

The lack of persistence of infused T cells is a principal limitation of adoptive immunotherapy in man. Interleukin (IL)-15 can sustain memory T cell expansion when presented in complex with IL-15Rα (15Rα/15). We developed a novel in-vitro system for generation of stable 15Rα/15 complexes. Immunologically quantifiable amounts of IL-15 were obtained when both IL-15Rα and IL-15 genes were co-transduced in NIH 3T3 fibroblast-based artificial antigen-presenting cells expressing human leucocyte antigen (HLA) A:0201, β2 microglobulin, CD80, CD58 and CD54 [A2-artificial antigen presenting cell (AAPC)] and a murine pro-B cell line (Baf-3) (A2-AAPC15Rα/15 and Baf-315Rα/15 ). Transduction of cells with IL-15 alone resulted in only transient expression of IL-15, with minimal amounts of immunologically detectable IL-15. In comparison, cells transduced with IL-15Rα alone (A2-AAPCRα ) demonstrated stable expression of IL-15Rα; however, when loaded with soluble IL-15 (sIL-15), these cells sequestered 15Rα/15 intracellularly and also demonstrated minimal amounts of IL-15. Human T cells stimulated in vitro against a viral antigen (CMVpp65) in the presence of 15Rα/15 generated superior yields of high-avidity CMVpp65 epitope-specific T cells [cytomegalovirus-cytotoxic T lymphocytes (CMV-CTLs)] responding to ≤ 10- 13 M peptide concentrations, and lysing targets cells at lower effector : target ratios (1 : 10 and 1 : 100), where sIL-15, sIL-2 or sIL-7 CMV-CTLs demonstrated minimal or no activity. Both soluble and surface presented 15Rα/15, but not sIL-15, sustained in-vitro expansion of CD62L+ and CCR7+ central memory phenotype CMV-CTLs (TCM ). 15Rα/15 complexes represent a potent adjuvant for augmenting the efficacy of adoptive immunotherapy. Such cell-bound or soluble 15Rα/15 complexes could be developed for use in combination immunotherapy approaches.
© 2016 British Society for Immunology.

Entities:  

Keywords:  T cell memory; adoptive immunotherapy; cancer immunotherapy; cytokine; immune adjuvant; immunomodulation

Mesh:

Substances:

Year:  2016        PMID: 27227483      PMCID: PMC5054569          DOI: 10.1111/cei.12816

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  58 in total

1.  Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

4.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.

Authors:  J B Latouche; M Sadelain
Journal:  Nat Biotechnol       Date:  2000-04       Impact factor: 54.908

5.  Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Authors:  Jianping Huang; Hung T Khong; Mark E Dudley; Mona El-Gamil; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

Review 6.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

7.  Selective induction of high avidity CTL by altering the balance of signals from APC.

Authors:  SangKon Oh; James W Hodge; Jeffrey D Ahlers; Donald S Burke; Jeffrey Schlom; Jay A Berzofsky
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

8.  Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells.

Authors:  Kimberly S Schluns; Kimberly D Klonowski; Leo Lefrançois
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

Review 9.  Homeostasis of naive and memory T cells.

Authors:  Charles D Surh; Jonathan Sprent
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

10.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  9 in total

Review 1.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 2.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

Review 3.  Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.

Authors:  Audrey Hubert; Nabila Seddiki
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

4.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.

Authors:  Lenka V Hurton; Harjeet Singh; Amer M Najjar; Kirsten C Switzer; Tiejuan Mi; Sourindra Maiti; Simon Olivares; Brian Rabinovich; Helen Huls; Marie-Andrée Forget; Vrushali Datar; Partow Kebriaei; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

5.  Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study.

Authors:  Jeong-Hoon Lee; Won Young Tak; Yoon Lee; Min-Kyu Heo; Jae-Sung Song; Hak-Yeop Kim; Soo Young Park; Si Hyun Bae; Joon Hyeok Lee; Jeong Heo; Ki-Hwan Kim; Yong-Soo Bae; Yoon Jun Kim
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

6.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27

Review 7.  Nanotechnology synergized immunoengineering for cancer.

Authors:  Deepak S Chauhan; Anupam Dhasmana; Partha Laskar; Rajendra Prasad; Nishant K Jain; Rohit Srivastava; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Eur J Pharm Biopharm       Date:  2021-03-24       Impact factor: 5.589

8.  Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.

Authors:  Serena Vitale; Caterina Strisciuglio; Laura Pisapia; Erasmo Miele; Pasquale Barba; Alessandra Vitale; Sabrina Cenni; Virginia Bassi; Mariantonia Maglio; Giovanna Del Pozzo; Riccardo Troncone; Annamaria Staiano; Carmen Gianfrani
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

9.  S-15 in combination of Akt inhibitor promotes the expansion of CD45RA-CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells.

Authors:  Benling Xu; Long Yuan; Guangyu Chen; Tiepeng Li; Jinxue Zhou; Chengjuan Zhang; Peng Qin; Musleh M Muthana; Shengdian Wang; Xuexiang Du; Quanli Gao
Journal:  Cancer Cell Int       Date:  2019-12-03       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.